Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR-γ pathway

Thymoquinone (TQ), an active ingredient of Nigella sativa, has been reported to exhibit anti-oxidant, anti-inflammatory and anti-tumor activities through mechanism(s) that is not fully understood. In this study, we report the anticancer effects of TQ on breast cancer cells, and its potential effect...

Full description

Bibliographic Details
Main Authors: Woo, C., Loo, S., Gee, V., Yap, C., Sethi, G., Kumar, Alan Prem, Benny Tan, K.
Format: Journal Article
Published: Elsevier 2011
Online Access:http://hdl.handle.net/20.500.11937/50131
_version_ 1848758402002452480
author Woo, C.
Loo, S.
Gee, V.
Yap, C.
Sethi, G.
Kumar, Alan Prem
Benny Tan, K.
author_facet Woo, C.
Loo, S.
Gee, V.
Yap, C.
Sethi, G.
Kumar, Alan Prem
Benny Tan, K.
author_sort Woo, C.
building Curtin Institutional Repository
collection Online Access
description Thymoquinone (TQ), an active ingredient of Nigella sativa, has been reported to exhibit anti-oxidant, anti-inflammatory and anti-tumor activities through mechanism(s) that is not fully understood. In this study, we report the anticancer effects of TQ on breast cancer cells, and its potential effect on the PPAR-γ activation pathway. We found that TQ exerted strong anti-proliferative effect in breast cancer cells and, when combined with doxorubicin and 5-fluorouracil, increased cytotoxicity. TQ was found to increase sub-G1 accumulation and annexin-V positive staining, indicating apoptotic induction. In addition, TQ activated caspases 8, 9 and 7 in a dose-dependent manner. Migration and invasive properties of MDA-MB-231 cells were also reduced in the presence of TQ. Interestingly, we report for the first time that TQ was able to increase PPAR-γ activity and down-regulate the expression of the genes for Bcl-2, Bcl-xL and survivin in breast cancer cells. More importantly, the increase in PPAR-γ activity was prevented in the presence of PPAR-γ specific inhibitor and PPAR-γ dominant negative plasmid, suggesting that TQ may act as a ligand of PPAR-γ. Also, we observed using molecular docking analysis that TQ indeed formed interactions with 7 polar residues and 6 non-polar residues within the ligand-binding pocket of PPAR-γ that are reported to be critical for its activity. Taken together, our novel observations suggest that TQ may have potential implication in breast cancer prevention and treatment, and show for the first time that the anti-tumor effect of TQ may also be mediated through modulation of the PPAR-γ activation pathway.
first_indexed 2025-11-14T09:43:25Z
format Journal Article
id curtin-20.500.11937-50131
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:43:25Z
publishDate 2011
publisher Elsevier
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-501312017-09-13T15:49:51Z Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR-γ pathway Woo, C. Loo, S. Gee, V. Yap, C. Sethi, G. Kumar, Alan Prem Benny Tan, K. Thymoquinone (TQ), an active ingredient of Nigella sativa, has been reported to exhibit anti-oxidant, anti-inflammatory and anti-tumor activities through mechanism(s) that is not fully understood. In this study, we report the anticancer effects of TQ on breast cancer cells, and its potential effect on the PPAR-γ activation pathway. We found that TQ exerted strong anti-proliferative effect in breast cancer cells and, when combined with doxorubicin and 5-fluorouracil, increased cytotoxicity. TQ was found to increase sub-G1 accumulation and annexin-V positive staining, indicating apoptotic induction. In addition, TQ activated caspases 8, 9 and 7 in a dose-dependent manner. Migration and invasive properties of MDA-MB-231 cells were also reduced in the presence of TQ. Interestingly, we report for the first time that TQ was able to increase PPAR-γ activity and down-regulate the expression of the genes for Bcl-2, Bcl-xL and survivin in breast cancer cells. More importantly, the increase in PPAR-γ activity was prevented in the presence of PPAR-γ specific inhibitor and PPAR-γ dominant negative plasmid, suggesting that TQ may act as a ligand of PPAR-γ. Also, we observed using molecular docking analysis that TQ indeed formed interactions with 7 polar residues and 6 non-polar residues within the ligand-binding pocket of PPAR-γ that are reported to be critical for its activity. Taken together, our novel observations suggest that TQ may have potential implication in breast cancer prevention and treatment, and show for the first time that the anti-tumor effect of TQ may also be mediated through modulation of the PPAR-γ activation pathway. 2011 Journal Article http://hdl.handle.net/20.500.11937/50131 10.1016/j.bcp.2011.05.030 Elsevier restricted
spellingShingle Woo, C.
Loo, S.
Gee, V.
Yap, C.
Sethi, G.
Kumar, Alan Prem
Benny Tan, K.
Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR-γ pathway
title Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR-γ pathway
title_full Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR-γ pathway
title_fullStr Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR-γ pathway
title_full_unstemmed Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR-γ pathway
title_short Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR-γ pathway
title_sort anticancer activity of thymoquinone in breast cancer cells: possible involvement of ppar-γ pathway
url http://hdl.handle.net/20.500.11937/50131